Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study Article Swipe
Vasilios M. Polymeropoulos
,
Leah Kiely
,
Margaret L. Bushman
,
Elizabeth B. Sutherland
,
Abigail Goldberg
,
Andy V. Pham
,
Cameron Miller
,
Raina Mourad
,
Tanner Davis
,
Nikolas Pham
,
Dane B. Morgan
,
A. Giles
,
Changfu Xiao
,
Christos Polymeropoulos
,
Gunther Birznieks
,
Mihael H. Polymeropoulos
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fneur.2025.1550670
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fneur.2025.1550670
Introduction Motion sickness has afflicted travelers since ancient times. Neurokinin-1 (NK1) receptor antagonists have therapeutic potential as treatments for the symptoms of motion sickness due to the widespread expression of NK1 receptors throughout important locations in the emetic pathway in the network of brainstem nuclei and the gut. This study evaluated the efficacy of tradipitant, a novel NK1 receptor antagonist, in preventing motion sickness symptoms in variable sea conditions. Methods A total of 365 adult participants with a history of motion sickness embarked on boat trips under variable sea conditions. Study participants were distributed across 34 boat trips that took place between November 2021 and April 2023 in coastal waters of the United States. Participants were randomized 1:1:1 and received 170 mg tradipitant ( n = 120), 85 mg tradipitant ( n = 123) or placebo ( n = 122). The symptoms of vomiting and nausea were evaluated with questionnaires every 30 min during the approximately four-hour trips. The primary efficacy endpoint for the study was the percentage of vomiting during vehicle travel. Statistical hypothesis testing was performed at the two-sided alpha level of 0.05 unless specified otherwise. Tests were declared statistically significant if the calculated p -value was ≤ 0.05. Results The incidence of vomiting in both dosing arms of tradipitant was significantly lower than the placebo group across all boat trips (170 mg tradipitant = 18.3%, 85 mg tradipitant = 19.5%, placebo = 44.3%, p < 0.0001 for both dose comparisons against placebo). Tradipitant prevented severe nausea and vomiting as compared to participants taking placebo (tradipitant = 18.03%, placebo = 37.70%, p < 0.0001). Discussion Tradipitant 170 mg and 85 mg have been confirmed to be effective in the prevention of vomiting associated with motion sickness across varied sea conditions. Clinical trial registration ClinicalTrials.gov , identifier NCT04327661.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fneur.2025.1550670
- https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdf
- OA Status
- gold
- References
- 41
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4408137168
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4408137168Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fneur.2025.1550670Digital Object Identifier
- Title
-
Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-03-04Full publication date if available
- Authors
-
Vasilios M. Polymeropoulos, Leah Kiely, Margaret L. Bushman, Elizabeth B. Sutherland, Abigail Goldberg, Andy V. Pham, Cameron Miller, Raina Mourad, Tanner Davis, Nikolas Pham, Dane B. Morgan, A. Giles, Changfu Xiao, Christos Polymeropoulos, Gunther Birznieks, Mihael H. PolymeropoulosList of authors in order
- Landing page
-
https://doi.org/10.3389/fneur.2025.1550670Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdfDirect OA link when available
- Concepts
-
Motion sickness, Placebo, Vomiting, Nausea, Medicine, Randomized controlled trial, Anesthesia, Internal medicine, Psychiatry, Alternative medicine, PathologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
41Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4408137168 |
|---|---|
| doi | https://doi.org/10.3389/fneur.2025.1550670 |
| ids.doi | https://doi.org/10.3389/fneur.2025.1550670 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40103934 |
| ids.openalex | https://openalex.org/W4408137168 |
| fwci | 0.0 |
| type | article |
| title | Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study |
| biblio.issue | |
| biblio.volume | 16 |
| biblio.last_page | 1550670 |
| biblio.first_page | 1550670 |
| topics[0].id | https://openalex.org/T10498 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9851999878883362 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2738 |
| topics[0].subfield.display_name | Psychiatry and Mental health |
| topics[0].display_name | Migraine and Headache Studies |
| topics[1].id | https://openalex.org/T12193 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9628999829292297 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Trigeminal Neuralgia and Treatments |
| topics[2].id | https://openalex.org/T10459 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9126999974250793 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2738 |
| topics[2].subfield.display_name | Psychiatry and Mental health |
| topics[2].display_name | Sexual function and dysfunction studies |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C2779336972 |
| concepts[0].level | 2 |
| concepts[0].score | 0.8806972503662109 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q309067 |
| concepts[0].display_name | Motion sickness |
| concepts[1].id | https://openalex.org/C27081682 |
| concepts[1].level | 3 |
| concepts[1].score | 0.76307213306427 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[1].display_name | Placebo |
| concepts[2].id | https://openalex.org/C2780852908 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7609574794769287 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q127076 |
| concepts[2].display_name | Vomiting |
| concepts[3].id | https://openalex.org/C2780580376 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7139719724655151 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q186889 |
| concepts[3].display_name | Nausea |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.6201468110084534 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C168563851 |
| concepts[5].level | 2 |
| concepts[5].score | 0.45903730392456055 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[5].display_name | Randomized controlled trial |
| concepts[6].id | https://openalex.org/C42219234 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4374930262565613 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q131130 |
| concepts[6].display_name | Anesthesia |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3697923421859741 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C118552586 |
| concepts[8].level | 1 |
| concepts[8].score | 0.1285020411014557 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7867 |
| concepts[8].display_name | Psychiatry |
| concepts[9].id | https://openalex.org/C204787440 |
| concepts[9].level | 2 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[9].display_name | Alternative medicine |
| concepts[10].id | https://openalex.org/C142724271 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[10].display_name | Pathology |
| keywords[0].id | https://openalex.org/keywords/motion-sickness |
| keywords[0].score | 0.8806972503662109 |
| keywords[0].display_name | Motion sickness |
| keywords[1].id | https://openalex.org/keywords/placebo |
| keywords[1].score | 0.76307213306427 |
| keywords[1].display_name | Placebo |
| keywords[2].id | https://openalex.org/keywords/vomiting |
| keywords[2].score | 0.7609574794769287 |
| keywords[2].display_name | Vomiting |
| keywords[3].id | https://openalex.org/keywords/nausea |
| keywords[3].score | 0.7139719724655151 |
| keywords[3].display_name | Nausea |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.6201468110084534 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[5].score | 0.45903730392456055 |
| keywords[5].display_name | Randomized controlled trial |
| keywords[6].id | https://openalex.org/keywords/anesthesia |
| keywords[6].score | 0.4374930262565613 |
| keywords[6].display_name | Anesthesia |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3697923421859741 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/psychiatry |
| keywords[8].score | 0.1285020411014557 |
| keywords[8].display_name | Psychiatry |
| language | en |
| locations[0].id | doi:10.3389/fneur.2025.1550670 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S96975567 |
| locations[0].source.issn | 1664-2295 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1664-2295 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Neurology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_lineage_names | Frontiers Media |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Neurology |
| locations[0].landing_page_url | https://doi.org/10.3389/fneur.2025.1550670 |
| locations[1].id | pmid:40103934 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in neurology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40103934 |
| locations[2].id | pmh:oai:doaj.org/article:6f464ca12a1f444dacfa2dd44908f749 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in Neurology, Vol 16 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/6f464ca12a1f444dacfa2dd44908f749 |
| locations[3].id | pmh:oai:europepmc.org:10729258 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11913704 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5040301246 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-5864-8198 |
| authorships[0].author.display_name | Vasilios M. Polymeropoulos |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[0].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[0].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[0].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Vasilios M. Polymeropoulos |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[1].author.id | https://openalex.org/A5093588917 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Leah Kiely |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[1].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[1].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[1].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Leah Kiely |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[2].author.id | https://openalex.org/A5093586842 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Margaret L. Bushman |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[2].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[2].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[2].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Margaret L. Bushman |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[3].author.id | https://openalex.org/A5102659827 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Elizabeth B. Sutherland |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[3].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[3].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[3].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | E. Blake Sutherland |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[4].author.id | https://openalex.org/A5065040200 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Abigail Goldberg |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[4].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[4].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[4].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Abigail R. Goldberg |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[5].author.id | https://openalex.org/A5084264214 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-1727-5054 |
| authorships[5].author.display_name | Andy V. Pham |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[5].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[5].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[5].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Annalise X. Pham |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[6].author.id | https://openalex.org/A5108926222 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Cameron Miller |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[6].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[6].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[6].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Cameron R. Miller |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[7].author.id | https://openalex.org/A5093588918 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Raina Mourad |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[7].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[7].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[7].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Raina Mourad |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[8].author.id | https://openalex.org/A5102659828 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Tanner Davis |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[8].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[8].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[8].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Tanner R. Davis |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[9].author.id | https://openalex.org/A5113197928 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Nikolas Pham |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[9].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[9].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[9].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Nikolas V. Pham |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[10].author.id | https://openalex.org/A5104294227 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Dane B. Morgan |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[10].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[10].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[10].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Dane B. Morgan |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[11].author.id | https://openalex.org/A5110362682 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-9957-9371 |
| authorships[11].author.display_name | A. Giles |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[11].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[11].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[11].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Abigail K. Giles |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[12].author.id | https://openalex.org/A5109033163 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Changfu Xiao |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[12].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[12].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[12].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Changfu Xiao |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[13].author.id | https://openalex.org/A5042907427 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-8920-8013 |
| authorships[13].author.display_name | Christos Polymeropoulos |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[13].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[13].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[13].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Christos M. Polymeropoulos |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[14].author.id | https://openalex.org/A5061765564 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Gunther Birznieks |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[14].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[14].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[14].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Gunther Birznieks |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[15].author.id | https://openalex.org/A5031674961 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-5065-5353 |
| authorships[15].author.display_name | Mihael H. Polymeropoulos |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210126775 |
| authorships[15].affiliations[0].raw_affiliation_string | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| authorships[15].institutions[0].id | https://openalex.org/I4210126775 |
| authorships[15].institutions[0].ror | https://ror.org/0394qmm90 |
| authorships[15].institutions[0].type | company |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210126775 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Vanda Pharmaceuticals (United States) |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Mihael H. Polymeropoulos |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Vanda Pharmaceuticals Inc., Washington, DC, United States |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10498 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9851999878883362 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2738 |
| primary_topic.subfield.display_name | Psychiatry and Mental health |
| primary_topic.display_name | Migraine and Headache Studies |
| related_works | https://openalex.org/W2134148966, https://openalex.org/W1981253214, https://openalex.org/W148728087, https://openalex.org/W2375265431, https://openalex.org/W2030053732, https://openalex.org/W4232799063, https://openalex.org/W2005374976, https://openalex.org/W2014292037, https://openalex.org/W4237990459, https://openalex.org/W1979418062 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fneur.2025.1550670 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S96975567 |
| best_oa_location.source.issn | 1664-2295 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1664-2295 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Neurology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_lineage_names | Frontiers Media |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Neurology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fneur.2025.1550670 |
| primary_location.id | doi:10.3389/fneur.2025.1550670 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S96975567 |
| primary_location.source.issn | 1664-2295 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1664-2295 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Neurology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_lineage_names | Frontiers Media |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550670/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Neurology |
| primary_location.landing_page_url | https://doi.org/10.3389/fneur.2025.1550670 |
| publication_date | 2025-03-04 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W6736185403, https://openalex.org/W6743164045, https://openalex.org/W1919013783, https://openalex.org/W3090637711, https://openalex.org/W6719811546, https://openalex.org/W1908712261, https://openalex.org/W6628607869, https://openalex.org/W3094049274, https://openalex.org/W2410173349, https://openalex.org/W2463893616, https://openalex.org/W6714183405, https://openalex.org/W1974232104, https://openalex.org/W1860985526, https://openalex.org/W2036804159, https://openalex.org/W2014845671, https://openalex.org/W1986621119, https://openalex.org/W32654342, https://openalex.org/W4390955721, https://openalex.org/W3042695204, https://openalex.org/W6601332088, https://openalex.org/W166703000, https://openalex.org/W2014779335, https://openalex.org/W1964223766, https://openalex.org/W1477430527, https://openalex.org/W3003000422, https://openalex.org/W4313535084, https://openalex.org/W146249114, https://openalex.org/W4230258258, https://openalex.org/W2465057753, https://openalex.org/W2158311073, https://openalex.org/W6801381017, https://openalex.org/W2177692849, https://openalex.org/W2991227964, https://openalex.org/W4240636065, https://openalex.org/W2047430703, https://openalex.org/W2144561279, https://openalex.org/W3200879147, https://openalex.org/W119592662, https://openalex.org/W2112111088, https://openalex.org/W568181250, https://openalex.org/W2750226814 |
| referenced_works_count | 41 |
| abstract_inverted_index.( | 123, 130, 136 |
| abstract_inverted_index., | 296 |
| abstract_inverted_index.= | 125, 132, 138, 226, 231, 234, 258, 261 |
| abstract_inverted_index.A | 70 |
| abstract_inverted_index.a | 55, 77 |
| abstract_inverted_index.n | 124, 131, 137 |
| abstract_inverted_index.p | 196, 236, 263 |
| abstract_inverted_index.30 | 151 |
| abstract_inverted_index.34 | 95 |
| abstract_inverted_index.85 | 127, 228, 271 |
| abstract_inverted_index.as | 16, 251 |
| abstract_inverted_index.at | 178 |
| abstract_inverted_index.be | 277 |
| abstract_inverted_index.if | 193 |
| abstract_inverted_index.in | 35, 39, 60, 65, 107, 206, 279 |
| abstract_inverted_index.mg | 121, 128, 224, 229, 269, 272 |
| abstract_inverted_index.of | 21, 29, 42, 53, 72, 79, 110, 142, 168, 183, 204, 210, 282 |
| abstract_inverted_index.on | 83 |
| abstract_inverted_index.or | 134 |
| abstract_inverted_index.to | 25, 253, 276 |
| abstract_inverted_index.170 | 120, 268 |
| abstract_inverted_index.365 | 73 |
| abstract_inverted_index.NK1 | 30, 57 |
| abstract_inverted_index.The | 140, 158, 202 |
| abstract_inverted_index.all | 220 |
| abstract_inverted_index.and | 45, 104, 118, 144, 249, 270 |
| abstract_inverted_index.due | 24 |
| abstract_inverted_index.for | 18, 162, 239 |
| abstract_inverted_index.has | 3 |
| abstract_inverted_index.min | 152 |
| abstract_inverted_index.sea | 67, 88, 290 |
| abstract_inverted_index.the | 19, 26, 36, 40, 46, 51, 111, 154, 163, 166, 179, 194, 216, 280 |
| abstract_inverted_index.was | 165, 176, 198, 212 |
| abstract_inverted_index.≤ | 199 |
| abstract_inverted_index.(170 | 223 |
| abstract_inverted_index.0.05 | 184 |
| abstract_inverted_index.123) | 133 |
| abstract_inverted_index.2021 | 103 |
| abstract_inverted_index.2023 | 106 |
| abstract_inverted_index.This | 48 |
| abstract_inverted_index.arms | 209 |
| abstract_inverted_index.been | 274 |
| abstract_inverted_index.boat | 84, 96, 221 |
| abstract_inverted_index.both | 207, 240 |
| abstract_inverted_index.dose | 241 |
| abstract_inverted_index.gut. | 47 |
| abstract_inverted_index.have | 13, 273 |
| abstract_inverted_index.than | 215 |
| abstract_inverted_index.that | 98 |
| abstract_inverted_index.took | 99 |
| abstract_inverted_index.were | 92, 115, 146, 189 |
| abstract_inverted_index.with | 76, 148, 285 |
| abstract_inverted_index.(NK1) | 10 |
| abstract_inverted_index.0.05. | 200 |
| abstract_inverted_index.120), | 126 |
| abstract_inverted_index.122). | 139 |
| abstract_inverted_index.1:1:1 | 117 |
| abstract_inverted_index.April | 105 |
| abstract_inverted_index.Study | 90 |
| abstract_inverted_index.Tests | 188 |
| abstract_inverted_index.adult | 74 |
| abstract_inverted_index.alpha | 181 |
| abstract_inverted_index.every | 150 |
| abstract_inverted_index.group | 218 |
| abstract_inverted_index.level | 182 |
| abstract_inverted_index.lower | 214 |
| abstract_inverted_index.novel | 56 |
| abstract_inverted_index.place | 100 |
| abstract_inverted_index.since | 6 |
| abstract_inverted_index.study | 49, 164 |
| abstract_inverted_index.total | 71 |
| abstract_inverted_index.trial | 293 |
| abstract_inverted_index.trips | 85, 97, 222 |
| abstract_inverted_index.under | 86 |
| abstract_inverted_index.-value | 197 |
| abstract_inverted_index.0.0001 | 238 |
| abstract_inverted_index.18.3%, | 227 |
| abstract_inverted_index.19.5%, | 232 |
| abstract_inverted_index.44.3%, | 235 |
| abstract_inverted_index.Motion | 1 |
| abstract_inverted_index.United | 112 |
| abstract_inverted_index.across | 94, 219, 288 |
| abstract_inverted_index.dosing | 208 |
| abstract_inverted_index.during | 153, 170 |
| abstract_inverted_index.emetic | 37 |
| abstract_inverted_index.motion | 22, 62, 80, 286 |
| abstract_inverted_index.nausea | 145, 248 |
| abstract_inverted_index.nuclei | 44 |
| abstract_inverted_index.severe | 247 |
| abstract_inverted_index.taking | 255 |
| abstract_inverted_index.times. | 8 |
| abstract_inverted_index.trips. | 157 |
| abstract_inverted_index.unless | 185 |
| abstract_inverted_index.varied | 289 |
| abstract_inverted_index.waters | 109 |
| abstract_inverted_index.18.03%, | 259 |
| abstract_inverted_index.37.70%, | 262 |
| abstract_inverted_index.Methods | 69 |
| abstract_inverted_index.Results | 201 |
| abstract_inverted_index.States. | 113 |
| abstract_inverted_index.against | 243 |
| abstract_inverted_index.ancient | 7 |
| abstract_inverted_index.between | 101 |
| abstract_inverted_index.coastal | 108 |
| abstract_inverted_index.history | 78 |
| abstract_inverted_index.network | 41 |
| abstract_inverted_index.pathway | 38 |
| abstract_inverted_index.placebo | 135, 217, 233, 256, 260 |
| abstract_inverted_index.primary | 159 |
| abstract_inverted_index.testing | 175 |
| abstract_inverted_index.travel. | 172 |
| abstract_inverted_index.vehicle | 171 |
| abstract_inverted_index.&lt; | 237, 264 |
| abstract_inverted_index.0.0001). | 265 |
| abstract_inverted_index.Clinical | 292 |
| abstract_inverted_index.November | 102 |
| abstract_inverted_index.compared | 252 |
| abstract_inverted_index.declared | 190 |
| abstract_inverted_index.efficacy | 52, 160 |
| abstract_inverted_index.embarked | 82 |
| abstract_inverted_index.endpoint | 161 |
| abstract_inverted_index.received | 119 |
| abstract_inverted_index.receptor | 11, 58 |
| abstract_inverted_index.sickness | 2, 23, 63, 81, 287 |
| abstract_inverted_index.symptoms | 20, 64, 141 |
| abstract_inverted_index.variable | 66, 87 |
| abstract_inverted_index.vomiting | 143, 169, 205, 250, 283 |
| abstract_inverted_index.afflicted | 4 |
| abstract_inverted_index.brainstem | 43 |
| abstract_inverted_index.confirmed | 275 |
| abstract_inverted_index.effective | 278 |
| abstract_inverted_index.evaluated | 50, 147 |
| abstract_inverted_index.four-hour | 156 |
| abstract_inverted_index.important | 33 |
| abstract_inverted_index.incidence | 203 |
| abstract_inverted_index.locations | 34 |
| abstract_inverted_index.performed | 177 |
| abstract_inverted_index.placebo). | 244 |
| abstract_inverted_index.potential | 15 |
| abstract_inverted_index.prevented | 246 |
| abstract_inverted_index.receptors | 31 |
| abstract_inverted_index.specified | 186 |
| abstract_inverted_index.travelers | 5 |
| abstract_inverted_index.two-sided | 180 |
| abstract_inverted_index.Discussion | 266 |
| abstract_inverted_index.associated | 284 |
| abstract_inverted_index.calculated | 195 |
| abstract_inverted_index.expression | 28 |
| abstract_inverted_index.hypothesis | 174 |
| abstract_inverted_index.identifier | 297 |
| abstract_inverted_index.otherwise. | 187 |
| abstract_inverted_index.percentage | 167 |
| abstract_inverted_index.preventing | 61 |
| abstract_inverted_index.prevention | 281 |
| abstract_inverted_index.randomized | 116 |
| abstract_inverted_index.throughout | 32 |
| abstract_inverted_index.treatments | 17 |
| abstract_inverted_index.widespread | 27 |
| abstract_inverted_index.Statistical | 173 |
| abstract_inverted_index.Tradipitant | 245, 267 |
| abstract_inverted_index.antagonist, | 59 |
| abstract_inverted_index.antagonists | 12 |
| abstract_inverted_index.comparisons | 242 |
| abstract_inverted_index.conditions. | 68, 89, 291 |
| abstract_inverted_index.distributed | 93 |
| abstract_inverted_index.significant | 192 |
| abstract_inverted_index.therapeutic | 14 |
| abstract_inverted_index.tradipitant | 122, 129, 211, 225, 230 |
| abstract_inverted_index.(tradipitant | 257 |
| abstract_inverted_index.Introduction | 0 |
| abstract_inverted_index.NCT04327661. | 298 |
| abstract_inverted_index.Neurokinin-1 | 9 |
| abstract_inverted_index.Participants | 114 |
| abstract_inverted_index.participants | 75, 91, 254 |
| abstract_inverted_index.registration | 294 |
| abstract_inverted_index.tradipitant, | 54 |
| abstract_inverted_index.approximately | 155 |
| abstract_inverted_index.significantly | 213 |
| abstract_inverted_index.statistically | 191 |
| abstract_inverted_index.questionnaires | 149 |
| abstract_inverted_index.ClinicalTrials.gov | 295 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5040301246 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 16 |
| corresponding_institution_ids | https://openalex.org/I4210126775 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/14 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Life below water |
| citation_normalized_percentile.value | 0.08706801 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |